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. The main causes of TBI are motor vehicle accidents (50%), falls (21%), assaults and violence (12%), sports and recreation (10%), and other (7%) 2 . TBI patients impose a tremendous burden on their families and society, and increase demands on the healthcare system. In order to achieve favorable outcomes, rapid diagnosis and treatment are important.
TBI triggers complex changes to the central nervous system (CNS). A better understanding of its complex pathobiology is required to further our ability to evaluate and care for brain injury patients. However, an understanding of the mechanisms and biomarkers of TBI remains elusive. Biomarkers reflecting the biological response to injury or disease have proven useful for diagnosing many disorders, including responses to injury, cancer, heart failure, infection, and genetic disorders (Table 1) 3 . Many biomarkers of TBI have been identified, although they are not widely used clinically. These markers include S-100ß, neuron specific enolase (NSE), glial fibrillary acid protein (GFAP), and myelin basic protein (MBP). Although these proteins are still being assessed, they appear to lack either the sensitivity or specificity (except GFAP) to be used effectively alone 4 . However, combinations of these markers can provide valuable information and effectively diagnose and predict the outcome of TBI
.
Given their potential utility for determining the diagnosis and prognosis of brain injuries, their clinical utility should be explored further.
Proteomic analysis is a powerful tool for the global evaluation of protein expression and has been applied widely in the analysis of disease 6 . Analyses of the TBI proteome can aid in our understanding of the association between protein changes and brain injury, and several studies have already applied proteomics to the identification of biomarkers for TBI
Proteomic analysis is a discovery-based method that invariably identifies many proteins that differ in abundance between control and experimental samples. TBI studies use samples such as brain tissue (often from animals), cerebrospinal fluid (CSF), and blood for proteomic analysis. These samples contain information related to the CNS. Of the proteins found in CSF samples, 76% were unique to that biofluid. By contrast, plasma and serum proteins have wide, dynamic concentration ranges and it is often difficult to discover a disease-specific biomarker within the background of blood-borne housekeeping proteins 7 . Consequently, the ideal samples for proteomic analysis are brain tissue and CSF.
METHOD

Animal model
Forty male Sprague-Dawley rats weighing 250-300 g were randomized into sham-operated or injury groups (n = 20/group). Rats were acclimated in a humidified room and maintained on a standard pellet diet at the Animal Center of Shanghai Jiao Tong University School of Medicine for 10 days before the experiment. The temperature in both the feeding and operating rooms was maintained at approximately 25 to 28°C. A fluid perfusion impact device was used to model TBI in the rats, as described previously 8 . All of the surgical, injury, and animal care protocols described below were approved by the Scientific and Ethics Committee of Shanghai Jiaotong University affiliated Sixth People's Hospital (Permit no. SYXK20130608). The rats in the TBI group were anesthetized with pentobarbital (3.5%, 40 mg/kg), shaved, and then placed in a stereotaxic frame. Surgery was performed as described by Sullivan and colleagues 9 . Briefly, a 6-mm ipsilateral craniotomy tangential to the bregma and the sagittal suture was made, leaving the underlying dura mater intact. A 5-mm-wide impactor tip was adjusted so that it just touched the exposed dura mater and was secured over the right parietal cortex. The next day, the animals were anesthetized, intubated, and then placed under a fluid-percussion brain injury device. A moderate fluidpercussion pulse (2.0 ± 0.2 atmospheres) was delivered to the right parietal cortex. Sham-operated rats underwent all of the surgical manipulations, but without the fluid-percussion pulse, and were monitored under anesthesia for 30 min after the sham operation. All of the animals were kept in the same environment after surgery for 48 hours.
Specimens
The sham-operated and TBI animals were anesthetized 48 h postoperatively and sacrificed by decapitation. Immediately following decapitation, the brain was removed and the cortex samples were dissected rapidly over dry ice. All of the samples were washed with ice-cold saline before freezing to reduce brain contamination with blood proteins. Samples were then stored in liquid nitrogen for further processing. Injured cortex samples were dissected to about 2 mm from the injury spot; sham samples were removed from the same location. The total time from decapitation to snap freezing of the samples was about 5 min for all animals in both groups.
Two-dimensional gel electrophoresis
First, 100 mg of tissue sample was ground into a powder in liquid nitrogen, homogenized in 1 ml of lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris-HCl, protease inhibitor mixture) on ice, and sonicated (10×10-s pulses) on ice. The homogenate was centrifuged at 12,000 rpm for 30 min at 4°C. The protein was precipitated with cold acetone at -20°C for 2 h and dissolved with rehydration buffer (8 M urea, 2 M thiourea, 4% CHAPS, 100 mM DTT, 2% ampholyte). Protein concentrations were determined using the Bradford method (Bio-Rad). Immobilized pH gradient (IPG) strips (18 cm, pH 4-7, non-linear; Bio-Rad) were rehydrated passively using 400 μl of rehydration buffer for 12 h at 17°C. Isoelectric focusing electrophoresis (IEF) was performed on an IEF cell (Bio-Rad). The strips were equilibrated in equilibration buffer (25 mM Tris-HCl (pH 8.8), 6 M urea, 20% glycerol, 2% SDS, 130 mM DTT) for 15 min and then in the same buffer containing 200 mM iodoacetamide instead of DTT for another 15 min. The two-dimensional gel electrophoresis (2-DE) separation was performed on 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) gels. The gels were stained using Coomassie Brilliant Blue R-350 (Merck), according to the supplier's protocol. In-gel tryptic digestion and protein identification by mass spectrometry In-gel tryptic digestion and protein identification by mass spectrometry (MS) were performed as described elsewhere 6 . Briefly, protein spots of interest were excised and destained. Ingel digestion was performed with 0.01 μg/μl trypsin (Promega) for 20 h at 37°C. The tryptic peptides were extracted from the gel and dried by centrifugal lyophilization. The peptide mixtures were redissolved in 0.5% trifluoroacetic acid (TFA) and analyzed on an AB4700 Proteomics Analyzer (Bruker Daltonics Inc.). Peptide mass maps were acquired in positive reflection mode, averaging 1,500 laser shots per matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) spectrum and 3,000 shots per TOF/TOF spectrum.
Data analysis
After gel staining, the protein spots were detected, quantified, and matched using PD-Quest 2D analysis software (BioRad). Each sample was run in triplicate. Protein identificated by mass spectrometry (MS), and the MS/MS data were assigned using a MASCOT search against the NCBInr database. Redundant proteins that appeared in the database under different names and accession numbers were eliminated. If more than one protein was identified in one spot, the single protein with the highest protein score was selected from the multiprotein family. Statistical calculations were performed by SPSS statistical software (version 16.0; SPSS, Inc.). Comparison between two groups was performed by Wilcoxon two-sample test. Statistical significance was defined as p < 0.05.
RESULTS
Differentially expressed proteins in the sham-operated and TBI groups
Contused brain cortex from TBI rats and brain cortex from sham-operated rats were analyzed in triplicate using 2-DE. Coomassie staining of the gels detected 405 and 371 protein spots within a pH range from 3-10 from the sham-operated and contused cortex, respectively (Figure 1) . Statistically, 80 protein spots were differentially expressed in the sham-operated and TBI rats brain cortices (p < 0.05).
Mass spectrum identification of differentially expressed proteins
The differentially expressed protein spots were subjected to MS/MS analysis. Twenty proteins were identified from the 80 spots (Table 2) . Of these, some were expressed more strongly in the sham-operated group (spot numbers: 49, 70, 109, 158, 231, 248, 254, 289 and 369), and others were expressed more strongly in the TBI group (spot numbers: 11, 31, 55, 97, 171, 300, 307, 358, 365, 387 and 388). MS/MS analysis showed these spots had different MASCOT scores and sequence coverage. The predicted molecular masses/pI values for the 20 spots are listed below, and fit the position of the corresponding spot on the 2-DE gel well (Table 2, Figure 2 ).
Of the 20 identified proteins, NSE, GFAP, S100B, αII-spectrin, and MAP2 have been studied as biomarkers of TBI (proteomic data not shown in Table 2 ). Tumor biomarkers such as 14-3-3 protein have not been studied in TBI. Proteins associated with cell apoptosis were also identified, such as GAPDH and RhoB. The other identified proteins have not been examined in relation to TBI and little is known regarding their function, such as nebulin-related anchoring protein and zinc finger protein 180.
DISCUSSION
This study used proteomic analyses to identify 20 proteins that were differentially expressed in the sham-operated and TBI groups of rats. These included proteins previously identified as biomarkers of TBI, such as NSE, GFAP, S100B, αII-spectrin, and MAP2. Others had not been identified in TBI patients or animals, including the tumor indicators M2-PK and 14-3-3 protein. The functions of some of the proteins that were identified after TBI have not been established.
NSE (spot no. 11) is a biomarker of TBI and has been studied in infants, children, and adults, and in mild and severe TBI. In clinical studies, serum NSE levels have been frequently studied. Berger et al. found that NSE was markedly increased in the CSF after severe TBI
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. NSE levels were significantly elevated in non-survivors as compared with survivors in adults 11 . Early elevation (≤ 3 days) of NSE secondary to severe TBI predicts deterioration to brain death. TopolovecVranic found that NSE was abnormally elevated in 65% of patients with TBI and predicted a poor outcome at 6 weeks post-injury 12 . NSE is also a candidate serum marker of impending cerebral hypoxia, which is elevated before the onset of clinical manifestations 13 . After multiple trauma, elevated NSE levels have been observed, but systemic NSE increased by similar degrees with and without TBI, limiting its ability to discriminate brain injury magnitude. Reports on correlations of serum NSE levels alone with clinical and neurological measures of brain injury magnitude and outcome have been controversial. NSE is not used widely clinically, perhaps because of the above and the lack of a large-scale, multi-center, randomized controlled study.
GFAP (spot no. 307) is a filament protein found in the astroglial cytoskeleton, is not found outside the CNS. GFAP could predictably discriminate between severe disability and vegetative state versus good and moderate outcomes as evaluated by the Glasgow Outcome Scale (GOS). A study of severe TBI patients confirmed its ability to predict mortality, and it was found to discriminate outcome categories of the GOS and Marshall CT classification. It also could discriminate between patients that had intracranial pressure (ICP) greater or less than 25 mm Hg, patients that had cerebral perfusion pressure greater or less than 60 mm Hg, and patients with mean arterial pressure greater or less than 60 mm Hg. GFAP shows good diagnostic potential to predict outcome after injury, and may also be valuable for diagnosing injury magnitude 14 . S100B (spot no. 387) is the most well studied proteins for TBI and is considered a promising, non-proprietary brain injury biomarker. S100B is most abundant in glial cells of the CNS and peripheral nervous system (Schwann cells). But this marker is that it is not exclusive to the brain, it can be found in other cells such as adipocytes and chondrocytes. A number of studies have demonstrated S100B's relationship to injury magnitude and outcome in TBI 5, 14 . However, some studies reported a poor value of S100B as a predictor of outcome after brain injury, particularly mild and pediatric TBI. A poor correlation was found between serum and brain S100B values, suggesting that the serum levels may depend primarily on the integrity of the blood-brain-barrier and do not reflect the S100B levels in the brain 6, 15 . Despite apparent controversy, S100B still has potential as a brain injury biomarker, and its preclinical and clinical utility should be further explored.
αII-spectrin (spot no. 97) is a major structural component of the neuron axonal cytoskeleton and a major proteolytic substrate for cysteine proteases involved in necrotic and apoptotic cell death. Many authors have examined αII-spectrin after TBI in rats or humans. αII-spectrin levels in the CSF were shown to increase after TBI in a rat model 16 . In patients, Brophy found that αII-spectrin breakdown products (SBDPs) were significantly elevated in patients with worse Glasgow Coma Scale (GCS) scores 24 h after injury compared to those whose GCS scores improved 17 . The mean CSF levels of SBDPs were significantly higher in TBI patients than in controls and in patients who died than in those who survived, and the SBDP concentration was significantly greater in TBI patients than in controls and was correlated with the GCS score
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. Therefore, αII-spectrin is an established biomarker of TBI.
MAP2 (spot no. 388) is important for microtubule stability and neural plasticity and appears to be among the most vulnerable of the cytoskeletal proteins following neuronal injury. Huh et al. found that MAP2 is an early, sensitive marker of neuronal damage following TBI. Early after TBI (2 hours) MAP2 expression decreased than that of control group. But in this study, we found that MAP2 was increased in TBI group. We speculate that the time of specimen harvesting led to this difference. In addition, MAP2 is an early blood marker in ischemic brain injury 19 . Therefore, MAP2 can be used as a marker for detecting neurotoxic insults, including ischemia and TBI.
There is a growing awareness that RhoB (spot no. 31) is also important signaling molecules in the CNS. RhoB is a member of the Rho GTPase family that is dramatically induced by brain ischemia or trauma. It seems likely that the increase in RhoB level plays a major role in determining the fate of the neurons, but there is little evidence as to whether the RhoB induction is beneficial or detrimental to neuronal survival. The increased RhoB expression promotes neurite outgrowth; but this increase is likely to make a substantial contribution to the neurodegenerative process, and also promotes caspase 3 activation and DNA fragmentation, key contributors to cell apoptosis 20 . RhoB mediates apoptosis in neoplastically transformed cells after DNA damage. Of the 20 proteins, GAPDH (spot no. 171) also participates in nuclear events, including transcription, RNA transport, DNA replication, and cell apoptosis 21 . Therefore, RhoB and GAPDH may play roles in neuro-cell apoptosis after TBI.
M2-PK (spot no. 49) is a phosphotyrosine-binding protein that has been studied in tumors, but not identified in TBI. M2-PK expression is critical for rapid growth in cancer cells 22 . It has been used in the diagnosis and surveillance of a variety of malignant diseases. With respect to injury, Oehler found that M2-PK expression and activity were increased in polytrauma patients compared to controls 23 . M2-PK is the product of the PKM2 gene. PKM2 gene transcription is activated by hypoxia-inducible factor 1 (HIF-1), i.e., when hypoxia occurs, such as after TBI, the PKM2 gene produces M2-PK. Pyruvate kinase (PK) orthologs in many organisms are inhibited by oxidants. Anastasiou found that the inhibition of M2-PK by reactive oxygen species contributes to cellular antioxidant responses 24 . Given the presence of hypoxia after TBI, M2-PK is a potential biomarker of TBI.
Another protein that has not previously been found after TBI is ATP-binding cassette protein C12 (spot no. 254). The gene for ATP-binding cassette protein C12 is Abcc12 in rats and ABCC12 in humans. The product of ABCC12 is MRP9, which is expressed in breast tissue, brain, bone, and ovary 25 . SUR1, the product of Abcc8, has been found in the CNS after TBI and has an effect on progressive hemorrhagic necrosis (PHN) 26 . Abcc8 and Abcc12 are members of the Abcc superfamily and their products, SUR1 and MRP9, respectively, have been found in brain. Therefore, similar to SUR1, MRP9 might be an indicator of TBI. The 14-3-3 protein (spot no. 387) family plays an important role in tumorigenesis and development. In addition, 14-3-3 protein is a biomarker of neurodegenerative diseases 27 . In the motoneurons of rats, Namikawa reported that enhanced expression of the molecules involved in Ras-Erk signaling, such as 14-3-3 protein, is required for peripheral nerve regeneration 28 . Apoptosis is important in cell death after TBI and is associated with B-cell lymphoma 2 (Bcl-2). 14-3-3 protein can bind Bcl-2-antagonist cell death (BAD) and then trigger cell apoptosis 29 . Consequently, 14-3-3 protein is a potential marker of apoptosis after TBI.
The remaining proteins, including leucine-, glutamate-, and lysine-rich protein 1, H(+)-transporting ATP synthase, nebulin-related anchoring protein, and zinc finger protein 180, have not been studied sufficiently and their functions after TBI have not been established. We can find no conclusive published relationships between these proteins and TBI. Therefore, more studies should target these proteins.
This study has several limitations. First, the study examined one time point after TBI (48 h), and the animal model was for moderate TBI. We did not determine protein expression at other times after TBI, nor did we determine protein expression in mild or severe TBI models. Second, the 20 proteins identified in the proteomic analysis have not been confirmed using Western blotting, immunohistochemistry, or reverse transcription polymerase chain reaction (RT-PCR) in animals or patients. Future work should focus on these limitations and identify protein expression at different time points in mild, moderate, and severe TBI, in animal models or in patients at one or more centers.
In general, this study validated several established biomarkers of TBI and identified other potential biomarkers that can be evaluated in the future.
